Renal cell carcinoma (RCC) is common with more than 60,000 new cases in the United States yearly. No curative therapies are available for metastatic RCC. Improved methods of imaging metastatic RCC would be of value in identifying sites of occult disease and potentially for judging response to therapy. A 58-year-old man with known metastatic clear cell RCC was imaged with both 18F-FDG and 18F-DCFPyL PET/CT. 18F-DCFPyL is a small molecule inhibitor of the prostate-specific membrane antigen (PSMA), a target known to be highly expressed on solid tumor neovasculature. Relative to 18F-FDG, 18F-DCFPyL identified more lesions and demonstrated higher tumor radiotracer uptake.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834697 | PMC |
| http://dx.doi.org/10.1097/RLU.0000000000000995 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
B-CLL with negative F-FDG PET/CT and intensive solitary lesion on PSMA PET/CT mimicking prostate cancer bone metastases.
EJNMMI Rep
January 2025
Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine & Endocrinology, University Hospital, Paracelsus Medical University Salzburg, Muellner Hauptstrasse 48, 5020, Salzburg, Austria.
Positron emission tomography/computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-radioligands is currently suggested by several clinical guidelines for the assessment of prostate cancer (PCa) in various clinical settings. However, PSMA will also be overexpressed in different cancers, which should be considered on the PSMA PET/CT reading in patients with concomitant neoplastic diseases. We report a case of 82-year-old male presented with prostate and history of oesophageal cancer and B-cell chronic lymphocytic leukemia (B-CLL).
View Article and Find Full Text PDF18F-DCFPyL in the Detection of Prostate Cancer Spread to the Lumbosacral Plexus.
Clin Nucl Med
December 2024
Department of Medical Imaging, McMaster University, Hamilton, Ontario, Canada.
In most cases, prostate cancer spreads locally to the seminal vesicles, via lymphatics to pelvic and abdominal lymph nodes, and hematogenously to the bones. Direct invasion along nerve roots is exceptionally rare but can occur. Here, we present a case with 18F-DCFPyL PET/CT images showing neoplastic involvement of the lumbosacral plexus in a patient with recurrent prostate cancer.
View Article and Find Full Text PDFClinical Factors Associated With Suspicious F-DCFPyL Prostate-Specific Membrane Antigen Positron Emission Tomography Activity in Patients Initially Managed With Radical Prostatectomy Including Prostate-Specific Antigen < 0.5 ng/mL.
J Urol
February 2025
Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
Purpose: There are limited data on prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/CT for workup of recurrence after radical prostatectomy (RP) at low PSA values. We evaluated a PSMA PET/CT cohort of patients post RP, focusing on patients with PSA < 0.5 ng/mL.
View Article and Find Full Text PDFProstate-specific membrane antigen PET versus [Tc]Tc-MDP bone scan for diagnosing bone metastasis in prostate cancer: a head-to-head comparative meta-analysis.
Front Med (Lausanne)
September 2024
Department of Urology Surgery, First Hospital of Jilin University, Changchun, China.
Purpose: To evaluate the diagnostic performance of PSMA PET/CT, including [Ga]Ga-PSMA-11 and [F]DCFPyL, in comparison with the [Tc]Tc-MDP bone scan (BS) in identifying bone metastases among prostate cancer patients.
Methods: A search was performed in the PubMed and Embase databases to locate pertinent publications from inception to February 12, 2024. The studies included were those that examined the diagnostic effectiveness of PSMA PET/CT (covering [Ga]Ga-PSMA-11 and [F]DCFPyL) compared to [Tc]Tc-MDP BS in identifying bone metastases among prostate cancer patients.
Association of Free-to-Total PSA Ratio and F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study.
J Nucl Med
November 2024
Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
In Canada and across the globe, access to PSMA PET/CT is limited and expensive. For patients with biochemical recurrence (BCR) after treatment for prostate cancer, novel strategies are needed to better stratify patients who may or may not benefit from a PSMA PET scan. The role of the free-to-total prostate-specific antigen (PSA) ratio (FPSAR) in posttreatment prostate cancer, specifically in the PSMA PET/CT era, remains unknown.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!